These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34198132)

  • 1. Racial/ethnic disparities in the use of medications for opioid use disorder (MOUD) and their effects on residential drug treatment outcomes in the US.
    Stahler GJ; Mennis J; Baron DA
    Drug Alcohol Depend; 2021 Sep; 226():108849. PubMed ID: 34198132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US.
    Stahler GJ; Mennis J
    Drug Alcohol Depend; 2020 Jul; 212():108067. PubMed ID: 32445926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes associated with medications for opioid use disorder (MOUD) among criminal justice-referred admissions to residential treatment in the U.S., 2015-2018.
    Stahler GJ; Mennis J; Stein LAR; Belenko S; Rohsenow DJ; Grunwald HE; Brinkley-Rubinstein L; Martin RA
    Drug Alcohol Depend; 2022 Jul; 236():109498. PubMed ID: 35605535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcome disparities for opioid users: Are there racial and ethnic differences in treatment completion across large US metropolitan areas?
    Stahler GJ; Mennis J
    Drug Alcohol Depend; 2018 Sep; 190():170-178. PubMed ID: 30041092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a disparity in medications for opioid use disorder based on race/ethnicity and gender? A systematic review and meta-analysis.
    Nedjat S; Wang Y; Eshtiaghi K; Fleming M
    Res Social Adm Pharm; 2024 Mar; 20(3):236-245. PubMed ID: 38101952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder.
    Friesen EL; Kurdyak P
    Drug Alcohol Depend; 2020 Nov; 216():108244. PubMed ID: 32861134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Explaining Racial-ethnic Disparities in the Receipt of Medication for Opioid Use Disorder during Pregnancy.
    Gao YA; Drake C; Krans EE; Chen Q; Jarlenski MP
    J Addict Med; 2022 Nov-Dec 01; 16(6):e356-e365. PubMed ID: 35245918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial/Ethnic Differences in the Medical Treatment of Opioid Use Disorders Within the VA Healthcare System Following Non-Fatal Opioid Overdose.
    Essien UR; Sileanu FE; Zhao X; Liebschutz JM; Thorpe CT; Good CB; Mor MK; Radomski TR; Hausmann LRM; Fine MJ; Gellad WF
    J Gen Intern Med; 2020 May; 35(5):1537-1544. PubMed ID: 31965528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis.
    Solomon KT; Bandara S; Reynolds IS; Krawczyk N; Saloner B; Stuart E; Connolly E
    J Subst Abuse Treat; 2022 Jan; 132():108424. PubMed ID: 34144299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
    Walley AY; Lodi S; Li Y; Bernson D; Babakhanlou-Chase H; Land T; Larochelle MR
    Addiction; 2020 Aug; 115(8):1496-1508. PubMed ID: 32096908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial and Ethnic Disparities in Outpatient Substance Use Disorder Treatment Episode Completion for Different Substances.
    Mennis J; Stahler GJ
    J Subst Abuse Treat; 2016 Apr; 63():25-33. PubMed ID: 26818489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How long does it take to complete outpatient substance use disorder treatment? Disparities among Blacks, Hispanics, and Whites in the US.
    Mennis J; Stahler GJ; El Magd SA; Baron DA
    Addict Behav; 2019 Jun; 93():158-165. PubMed ID: 30711669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.
    Krawczyk N; Williams AR; Saloner B; Cerdá M
    J Subst Abuse Treat; 2021 Jul; 126():108329. PubMed ID: 34116820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital Addiction Medicine Consultation Service Orders and Outcomes by Patient Race and Ethnicity in an Urban, Safety-Net Hospital.
    Lindsay AR; Winkelman TNA; Bart G; Rhodes MT; Shearer RD
    J Gen Intern Med; 2024 Feb; 39(2):168-175. PubMed ID: 37552419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.
    Askari MS; Martins SS; Mauro PM
    J Subst Abuse Treat; 2020 Jul; 114():108028. PubMed ID: 32527510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
    Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
    J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residential and outpatient treatment completion for substance use disorders in the U.S.: Moderation analysis by demographics and drug of choice.
    Stahler GJ; Mennis J; DuCette JP
    Addict Behav; 2016 Jul; 58():129-35. PubMed ID: 26925821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial/ethnic residential segregation and the availability of opioid and substance use treatment facilities in US counties, 2009-2019.
    DiNardi M; Swann WL; Kim SY
    SSM Popul Health; 2022 Dec; 20():101289. PubMed ID: 36457346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adolescent-Serving Addiction Treatment Facilities in the United States and the Availability of Medications for Opioid Use Disorder.
    Alinsky RH; Hadland SE; Matson PA; Cerda M; Saloner B
    J Adolesc Health; 2020 Oct; 67(4):542-549. PubMed ID: 32336560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness.
    Han BH; Doran KM; Krawczyk N
    J Subst Abuse Treat; 2022 Jan; 132():108504. PubMed ID: 34102461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.